Clinical features and prognosis in heart failure patients with chronic obstructive pulmonary diseases

Background. Multimorbidity is a specific characteristic of the modern patient with chronic heart failure (CHF) which significantly changes clinical course, prognosis of the syndrome, leads to socio‑economic losses and makes significant adjustments to treatment tactics. The goal is to study the clinical features and prognosis of patients with CHF in combination with chronic obstructive pulmonary disease (COPD). Materials and methods. We studied 183 HF patients, including with stable CHF, including 105 with CHF combined with COPD. The clinical phenotype was assessed by its belonging to the functional class and the severity of COPD. A 6‑minute walk test (6‑MWT), spirometry, echocardioscopy, testing on a scale assessing the clinical condition, quality of life were studied. The end points during the year were: all‑cause mortality and cardiovascular mortality, myocardial infarction, stroke, pulmonary embolism, and hospitalization rates due to acute decompensation of CHF. Results. The clinical phenotype of CHF combined with COPD was characterized by a high frequency of smoking, low quality of life and exercise tolerance. Respiratory dysfunction in CHF in combination with COPD was characterized by mixed disorders (68.4%), in CHF without lung disease, restrictive (25.6%). Cardiovascular mortality in comorbid pathology was 4.0%, in CHF without COPD – 4.6%; myocardial infarction was observed 1.7 times more often with lung disease than in patients with CHF only (16.8% and 10.8%); stroke was observed exclusively in comorbid pathology (8.9%). The combined endpoint (all cardiovascular events) with CHF in combination with COPD was achieved 2.3 times more often in comparison with patients with COPD only (29.7% and 15.4%). Hospitalization due to acute decompensation of CHF occurred 2 times more often with CHF in combination with COPD than without it (32.7% and 15.4%) with a tendency to increase as the left ventricular ejection fraction decreased. Conclusion. The results of the study demonstrate that COPD contributes to the formation of the clinical phenotype of CHF from the standpoint of the mutual influence of the characteristics of the cardiovascular and respiratory systems, and also aggravates the prognosis that requires an integrated approach to the differential diagnosis and individualization of pharmacotherapy.

1. Correia L.L., Lebedev T.Yu., Efremova O.A., Proschaev K.I., Litovchenko E.S. The problem of polymorbidity with a combination of chronic obstructive pulmonary disease and certain cardiovascular diseases. Scientifc statements of Belgorod State University. Series: Medicine. Pharmacy. 2013;4 (147):12–7. [Russian: Коррейа Л.Л., Лебедев Т.Ю., Ефремова О.А., Прощаев К.И., Литовченко Е.С. Проблема полиморбидности при сочетании хронической обструктивной болезни легких и некоторых сердечно-сосудистых заболеваний. Научные ведомости Белгородского государственного университета. Серия: Медицина. Фармация. 2013;4(147):12–7]

2. Oganov R.G., Denisov I.N., Simanenkov V.I., Bakulin I.G., Bakulina N.V., Boldueva S.A. et al. Comorbidities in practice. Clinical guidelines. Cardiovascular therapy and prevention. 2017;16 (6):5–56. [Russian: Оганов Р.Г., Денисов И.Н., Симаненков В.И., Бакулин И.Г., Бакулина Н.В., Болдуева С.А. и др. Коморбидная патология в клинической практике. Клинические рекомендации. Кардиоваскулярная терапия и профилактика. 2017;16(6):5-56]. DOI: 10.15829/1728-8800-2017-6-5-56

3. Rushton CA, Satchithananda DK, Jones PW, Kadam UT. Noncardiovascular comorbidity, severity and prognosis in non-selectedheart failure populations: A systematic review and meta-analysis.International Journal of Cardiology. 2015; 196:98–106. DOI: 10.1016/j.ijcard.2015.05.180

4. Canepa M, Temporelli PL, Rossi A, Rossi A, Gonzini L, Nicolosi GL et al. Prevalence and Prognostic Impact of Chronic Obstructive Pulmonary Disease in Patients with Chronic Heart Failure: Data from the GISSI-HF Trial. Cardiology. 2017;136(2):128–37. DOI: 10.1159/000448166

5. Chen W, Tomas J, Sadatsafavi M, FitzGerald JM. Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. The Lancet Respiratory Medicine. 2015;3(8):631–9. DOI: 10.1016/S2213-2600(15)00241-6

6. Ruten FH, Cramer M-JM, Grobbee DE, Sachs APE, Kirkels JH, Lammers J-WJ et al. Unrecognized heart failure in elderly patients with stable chronic obstructive pulmonary disease. European Heart Journal. 2005;26(18):1887–94. DOI: 10.1093/eurheartj/ehi291

7. Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. The Lancet. 2007;370(9589):765–73. DOI: 10.1016/S0140-6736(07)61380-4

8. Ruten FH. β-Blockers May Reduce Mortality and Risk of Exacerbations in Patients With Chronic Obstructive Pulmonary Disease. Archives of Internal Medicine. 2010;170(10):880–7. DOI: 10.1001/archinternmed.2010.112

9. Hawkins NM, Huang Z, Pieper KS, Solomon SD, Kober L, Velazquez EJ et al. Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). European Journal of Heart Failure. 2009;11(3):292–8. DOI: 10.1093/eurjhf/hfp001

10. O’Kelly N. Short-term outcomes in heart failure patients with chronic obstructive pulmonary disease in the community. World Journal of Cardiology. 2012;4(3):66–71. DOI: 10.4330/wjc.v4.i3.66

11. Plesner LL, Dalsgaard M, Schou M, Køber L, Vestbo J, Kjøller E et al. The prognostic signifcance of lung function in stable heart failure outpatients. Clinical Cardiology. 2017;40(11):1145–51. DOI: 10.1002/clc.22802

12. Hawkins NM. Chronic obstructive pulmonary disease and heart failure in Europe-further evidence of the need for integrated care: Editorial comment. European Journal of Heart Failure. 2018;20(1):111–3. DOI: 10.1002/ejhf.986

13. Honda Y, Watanabe T, Otaki Y, Tamura H, Nishiyama S, Takahashi H et al. Impact of reduced forced expiratory volume on cardiac prognosis in patients with chronic heart failure. Heart and Vessels. 2018;33(9):1037–45. DOI: 10.1007/s00380-018-1153-1

14. Ardashev A.V., Shlyakhto E.V., Arutiunov G.P., Belenkov Yu.N. National guidelines for risk identifcation and prevention of sudden cardiac death. Clinical Practice. 2012;4 (12):1–77. [Russian: Ардашев А.В., Шляхто Е.В., Арутюнов Г.П., Беленков Ю.Н. Национальные рекомендации по определению риска и профилактике внезапной сердечной смерти. Клиническая практика. 2012;4(12):1-77]

15. Mareev V.Yu., Ageev F.T., Arutiunov G.P., Koroteev A.V., Revishvili A.Sh., Belenkov Yu.N. et al. National recommendations of VNOK and SSHF on the diagnostics and treatment of chronic heart failure (third review) Approved by OSSN Conference, December 15, 2009. Russian Heart Failure Journal. 2010;11 (1):3–62. [Russian: Мареев В.Ю., Агеев Ф.Т., Арутюнов Г.П., Коротеев А.В., Ревишвили А.Ш., Беленков Ю.Н. и др. Национальные рекомендации ВНОК и ОССН по диагностике и лечению ХСН (третий пересмотр). (Утверждены конференцией ОССН 15 декабря 2009 года). Журнал Сердечная Недостаточность. 2010;11(1):3–62]

16. Chuchalin A.G., Aisanov Z.R., Chikina S.Yu., Chernyak A.V., Kalmanova E.N. Federal clinical recommendations of the Russian respiratory society on the use of spirometry. Pulmonology. 2014;6:11–24. [Russian: Чучалин А.Г., Айсанов З.Р., Чикина С.Ю., Черняк А.В., Калманова Е.Н. Федеральные клинические рекомендации Российского респираторного общества по использованию метода спирометрии. Пульмонология. 2014;6:11-24]

17. Braga JR, Tu JV, Austin PC, Sutradhar R, Ross HJ, Lee DS. Recurrent events analysis for examination of hospitalizations in heart failure: insights from the Enhanced Feedback for Effective Cardiac Treatment (EFFECT) trial. European Heart Journal - Quality of Care and Clinical Outcomes. 2018;4(1):18–26. DOI: 10.1093/ehjqcco/qcx015

18. Karoli N.A., Borodkin A.V., Rebrov A.P. Different origins of chronic heart failure in patients with chronic obstructive pulmonary disease. Pulmonology. 2016;26 (1):38–45. [Russian: Кароли Н.А., Бородкин А.В., Ребров А.П. Хроническая сердечная недостаточность различного генеза у больных хронической обструктивной болезнью легких. Пульмонология. 2016;26(1):38-45]. DOI: 10.18093/08690189-2016-26-1-38-45

19. Iversen KK, Kjaergaard J, Akkan D, Kober L, Torp-Pedersen C, Hassager C et al. Chronic obstructive pulmonary disease in patients admited with heart failure. Journal of Internal Medicine. 2008;264(4):361–9. DOI: 10.1111/j.1365-2796.2008.01975.x

20. Mentz RJ, Kelly JP, von Lueder TG, Voors AA, Lam CSP, Cowie MR et al. Noncardiac Comorbidities in Heart Failure with Reduced Versus Preserved Ejection Fraction. Journal of the American College of Cardiology. 2014;64(21):2281–93. DOI: 10.1016/j.jacc.2014.08.036

21. Valk M, Broekhuizen B, Mosterd A, Zuithoff NPA, Hoes A, Ruten F. COPD in patients with stable heart failure in the primary care setting. International Journal of Chronic Obstructive Pulmonary Disease. 2015;10:1219–24. DOI: 10.2147/COPD.S77085

22. Watz H, Waschki B, Meyer T, Kretschmar G, Kirsten A, Claussen M et al. Decreasing Cardiac Chamber Sizes and Associated Heart Dysfunction in COPD. Chest. 2010;138(1):32–8. DOI: 10.1378/chest.09-2810

23. Koziolova N.A., Masalkina O.V., Kozlova E.V. Regularities in development of chronic heart failure in patients with ischemic heart disease and chronic obstructive pulmonary disease associated with multiple comorbidity. Russian Heart Failure Journal. 2016;17(3):151–63. [Russian: Козиолова Н.А., Масалкина О.В., Козлова Е.В. Закономерности формирования хронической сердечной недостаточности у больных ишемической болезнью сердца и хронической обструктивной болезнью легких на фоне множественной коморбидной патологии. Журнал Сердечная Недостаточность. 2016;17(3):151–63]. DOI: 10.18087/rhf.2016.3.2222

24. Dalsgaard M, Plesner LL, Schou M, Kjøller E, Vestbo J, Iversen K. Prevalence of airflow obstruction in patients with stable systolic heart failure. BMC Pulmonary Medicine. 2017;17(1):6. DOI: 10.1186/s12890-016-0351-9

25. Khaletskaya A. I., Kuznetsov A. N., Shcherbinina E. V., Fomin I.V. Peculiarities of comorbid course of chronic obstructive pulmonary disease and chronic cardiac insufciency and their influence on patients life quality. Medical Almanac. 2017;3 (48):206–10. [Russian: Халецкая А.И., Кузнецов А.Н., Щербинина Е.В., Фомин И.В. Особенности коморбидного течения хронической обструктивной болезни легких и хронической сердечной недостаточности и их влияние на качество жизни пациентов. Медицинский альманах. 2017;3(48):206-10]

26. Karas’kov A. M., Kamenskaya O.V., Klinkova A.S., Cherniavsky A.M. Chronic heart failure and external respiratory function in patients with ischemic heart disease. Russian Heart Failure Journal. 2014;15 (2):90–4. [Russian: Караськов А.М., Каменская О.В., Клинкова А.С., Чернявский А.М. Хроническая сердечная недостаточность и состояние функции внешнего дыхания у пациентов с ишемической болезнью сердца. Журнал Сердечная Недостаточность. 2014;15(2):90-4]

27. Polyakov D.S., Fomin I.V., Valikulova F.Yu., Vaisberg A.R., Kraiem N., Badin Yu.V. et al. The EPOCH-CHF epidemiological program: decompensated chronic heart failure in real-life clinical practice (EPOCH-D–CHF). Russian Heart Failure Journal. 2016;17 (5):299–305. [Russian: Поляков Д.С., Фомин И.В., Валикулова Ф.Ю., Вайсберг А.Р., Краием Н., Бадин Ю.В. и др. Эпидемиологическая программа ЭПОХА-ХСН: Декомпенсация хронической сердечной недостаточности в реальной клинической практике (ЭПОХА-Д-ХСН). Журнал Сердечная Недостаточность. 2016;17(5):299–305]. DOI: 10.18087/rhf.2016.5.2239

28. Canepa M, Straburzynska-Migaj E, Drozdz J, Fernandez-Vivancos C, Pinilla JMG, Nyolczas N et al. Characteristics, treatments and 1-year prognosis of hospitalized and ambulatory heart failure patients with chronic obstructive pulmonary disease in the European Society of Cardiology Heart Failure Long-Term Registry: Chronic obstructive pulmonary disease in heart failure. European Journal of Heart Failure. 2018;20(1):100–10. DOI: 10.1002/ejhf.964

29. Sitnikova M.Yu., Lelyavina T.A., Fedotov P.A., Trukshina M.A., Dorofeikov V.V., Shlyakhto E.V. Risk stratifcation in ambulatory patients with heart failure and chronic obstructive pulmonary disease: evaluation of predictive value of standard prognostic markers for 5-years survival. Arterial Hypertension. 2009;15 (2):132–7. [Russian: Ситникова М.Ю., Лелявина Т.А., Федотов П.А., Трукшина М.А., Дорофейков В.В., Шляхто Е.В. Влияние прогностических маркеров, оцениваемых в рутинной клинической практике, на 5-летнюю выживаемость больных хронической сердечной недостаточностью и сопутствующей хронической обструктивной болезнью легких. Артериальная гипертензия. 2009;15(2):132-7]

30. Prokopova L.V., Kashuba S.M., Galenko V.L., Fedotov P.A., Smirnov B.I., Sitnikova M.Yu. Role of simple clinico-laboratory parameters in oneyear prediction of lEF HF course in the epoch of high-tech methods of health care: the available prognosis study. Russian Heart Failure Journal. 2015;16 (3):137–44. [Russian: Прокопова Л.В., Кашуба С.М., Галенко В.Л., Федотов П.А., Смирнов Б.И., Ситникова М.Ю. Роль простых клинико-лабораторных показателей в одногодичном прогнозировании течения СН-нФВ в эпоху высокотехнологичных методов помощи: исследование «Доступный прогноз». Журнал Сердечная Недостаточность. 2015;16(3):137-44]

31. Eriksson B, Wändell P, Dahlström U, Näsman P, Lund LH, Edner M. Comorbidities, risk factors and outcomes in patients with heart failure and an ejection fraction of more than or equal to 40% in primary care- and hospital care-based outpatient clinics. Scandinavian Journal of Primary Health Care. 2018;36(2):207–15. DOI: 10.1080/02813432.2018.1459654